Aduro buries another cancer vaccine after CRS-207 joins the lineup of clinical disasters
After sticking it out through a partial hold and earlier clinical trial setbacks, Aduro $ADRO is finally washing its hands of a cancer vaccine that represented its most advanced clinical program.
About 18 months after a combination of GVAX and CRS-207 missed the mark on pancreatic cancer, compared to chemo, the Berkeley, CA-based biotech is throwing in the trial on CRS-207, which the biotech had held on to in order to pursue some clinical evidence of efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.